BIOMARIN PHARMACEUTICAL INC Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) of $13.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet · last filed 2017-02-27
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $11.80M.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2016-09-30 was -$1.10M.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2016-06-30 was -$200.00K.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $2.50M, a 89.80% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2016 was $13.00M, a 4.41% decline from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2015 was $13.60M, a 14.47% decline from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2014 was $15.90M.
- BIOMARIN PHARMACEUTICAL INC derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2013 was -$2.40M, a 1300.00% decline from fiscal 2012.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 12 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $10.70M derived: sum of 2 quarters · filed 2017-02-27 | $10.50M derived: sum of 3 quarters · filed 2017-02-27 | $13.00M 10-K · filed 2017-02-27 | |
| 2016-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$1.30M derived: sum of 2 quarters · filed 2016-11-03 | $1.20M 10-Q · filed 2016-11-03 | -$200.00K derived: sum of 4 quarters · filed 2017-02-27 | |
| 2016-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $2.30M 10-Q · filed 2016-08-08 | $900.00K derived: sum of 3 quarters · filed 2017-02-27 | -$1.20M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2016-03-31 | $2.50M 10-Q · filed 2016-05-02 | $1.10M derived: sum of 2 quarters · filed 2017-02-27 | -$1.00M derived: sum of 3 quarters · filed 2017-02-27 | -$8.40M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$3.50M derived: sum of 2 quarters · filed 2017-02-27 | -$10.90M derived: sum of 3 quarters · filed 2017-02-27 | $13.60M 10-K · filed 2017-02-27 | |
| 2015-09-30 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$9.50M derived: sum of 2 quarters · filed 2015-11-02 | $15.00M 10-Q · filed 2015-11-02 | $19.60M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-06-30 | -$7.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $17.10M 10-Q · filed 2015-08-05 | $21.70M derived: sum of 3 quarters · filed 2017-02-27 | $32.10M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-03-31 | $24.50M 10-Q · filed 2015-05-05 | $29.10M derived: sum of 2 quarters · filed 2017-02-27 | $39.50M derived: sum of 3 quarters · filed 2017-02-27 | $39.30M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2014-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $15.00M derived: sum of 2 quarters · filed 2017-02-27 | $14.80M derived: sum of 3 quarters · filed 2017-02-27 | $15.90M 10-K · filed 2017-02-27 | |
| 2014-09-30 | $10.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $10.20M derived: sum of 2 quarters · filed 2014-10-28 | $11.30M 10-Q · filed 2014-10-28 | $11.00M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $900.00K 10-Q · filed 2014-07-31 | $600.00K derived: sum of 3 quarters · filed 2016-02-29 | -$2.70M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $1.10M 10-Q · filed 2014-05-02 | $800.00K derived: sum of 2 quarters · filed 2016-02-29 | -$2.50M derived: sum of 3 quarters · filed 2016-02-29 | -$2.80M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$3.60M derived: sum of 2 quarters · filed 2016-02-29 | -$3.90M derived: sum of 3 quarters · filed 2016-02-29 | -$2.40M 10-K · filed 2016-02-29 | |
| 2013-09-30 | -$3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$3.60M derived: sum of 2 quarters · filed 2013-10-28 | -$2.10M 10-Q · filed 2013-10-28 | ||
| 2013-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $1.20M 10-Q · filed 2013-07-29 | |||
| 2013-03-31 | $1.50M 10-Q · filed 2013-04-29 | ||||
| 2012-12-31 | $200.00K 10-K · filed 2015-03-02 | -$200.00K 10-Q · filed 2013-04-29 | |||
| 2011-12-31 | -$8.00M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |